retracted
DOI:
https://doi.org/10.70749/ijbr.v3i6.1798Keywords:
Dyslipidemia, Type II Diabetes Mellitus, HDL-C, LDL-C, HbA1c, Cardiovascular Risk, Lipid AbnormalitiesAbstract
retracted
Downloads
References
1. Al-Adsani, A., Memon, A., & Suresh, A. (2004). Pattern and determinants of dyslipidaemia in type 2 diabetes mellitus patients in Kuwait. Acta Diabetologica, 41(3), 129-135.
https://doi.org/10.1007/s00592-004-0156-9
2. International diabetes federation diabetes atlas. 7th ed.
https://www.diabetesatlas.org/
3. HAYAT, S., PATEL, B., KHATTAR, R., & MALIK, R. (2004). Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clinical Science, 107(6), 539-557.
https://doi.org/10.1042/cs20040057
4. American Diabetes Association. (2004). Dyslipidemia management in adult with diabetes. Diabetes Care. Diabetes Care, 27(suppl_1), s68-s71.
https://doi.org/10.2337/diacare.27.2007.s68
5. Singh, G., & Kumar, A. (2011). Relationship among HbAlc and lipid profile in Punajbi type 2 diabetic population. Journal of Exercise Science and Physiotherapy, 7(2), 99.
https://doi.org/10.18376//2011/v7i2/67614
6. Langsted, A., & Nordestgaard, B. G. (2011). Nonfasting lipids, lipoproteins, and Apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen general population study. Clinical Chemistry, 57(3), 482-489.
https://doi.org/10.1373/clinchem.2010.157164
7. UK, N. C. G. C. (2014). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
8. Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., Chapman, M. J., Cobbaert, C., Descamps, O. S., Von Eckardstein, A., Kamstrup, P. R., Pulkki, K., Kronenberg, F., Remaley, A. T., Rifai, N., … Langlois, M. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration Cutpoints—A joint consensus statement from the European atherosclerosis society and European Federation of clinical chemistry and laboratory medicine. Clinical Chemistry, 62(7), 930-946.
https://doi.org/10.1373/clinchem.2016.258897
9. Qi, L., Ding, X., Tang, W., Li, Q., Mao, D., & Wang, Y. (2015). Prevalence and risk factors associated with Dyslipidemia in Chongqing, China. International Journal of Environmental Research and Public Health, 12(10), 13455-13465.
https://doi.org/10.3390/ijerph121013455
10. Bhandari, G. P., Angdembe, M. R., Dhimal, M., Neupane, S., & Bhusal, C. (2014). State of non-communicable diseases in Nepal. BMC Public Health, 14(1), 1-9.
https://doi.org/10.1186/1471-2458-14-23
11. Pokharel, D. R., Khadka, D., Sigdel, M., Yadav, N. K., Acharya, S., Kafle, R., Sapkota, R. M., & Sigdel, T. (2017). Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes. BMC Research Notes, 10(1).
https://doi.org/10.1186/s13104-017-2465-4
12. Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013). Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs, 73(4), 327-339.
https://doi.org/10.1007/s40265-013-0023-5
13. Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005). Type 2 diabetes as a “Coronary heart disease equivalent”. Diabetes Care, 28(12), 2901-2907.
https://doi.org/10.2337/diacare.28.12.2901
14. Talat, N., Aamir, K., Gulsena, M., Bilal, B. Y., & MA, C. (2003). Dyslipidemias in type II diabetes mellitus patients in a teaching hospital of Lahore, Pakistan. Pak J Med Sci, 19(4), 283–286.
15. Dm, N. (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 49, 1711-1721.
https://cir.nii.ac.jp/crid/1570291225513645696
16. Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology, 5(3), 150-159.
https://doi.org/10.1038/ncpendmet1066
17. Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology, 5(3), 150-159.
https://doi.org/10.1038/ncpendmet1066
18. Goldberg, I. J. (2001). Diabetic Dyslipidemia: Causes and consequences. Journal of Clinical Endocrinology & Metabolism, 86(3), 965-971.
https://doi.org/10.1210/jc.86.3.965
19. American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care, 46(Suppl 1), S123–S138.
20. Khan SA, Arif M, Bano S, Khan NA. Dyslipidemia in type 2 diabetes mellitus patients in a tertiary care hospital, Peshawar. J Ayub Med Coll Abbottabad. 2017;29(1):31–35.
21. Agarwal AK, Singh S. Dyslipidemia in newly diagnosed type 2 diabetes mellitus patients: pattern and predictors. J Assoc Physicians India. 2016;64(11):14–17.
22. Anwar M, Iqbal SP, Khurshid M. Gender differences in dyslipidemia patterns among diabetic patients. Diabetes Metab Syndr. 2019;13(2):1235–1239.
23. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England journal of medicine, 339(4), 229-234.
https://doi.org/10.1056/NEJM199807233390404
24. Yadav S, Bhattarai D, Yadav NK. Prevalence of dyslipidemia among type 2 diabetes patients in Eastern Nepal. J Nepal Med Assoc. 2020;58(229):275–279.
25. Younis BB, Riaz M, Altaf M. Frequency of dyslipidemia in type 2 diabetics. Saudi Med J. 2015;36(10):1260–1263.
26. Kumar A, Singh R, Singh N. Correlation of lipid profile with HbA1c in T2DM. Int J Contemp Med Res. 2016;3(4):1006–1009.
27. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet, 352(9131), 837-853.
https://doi.org/10.1016/S0140-6736(98)07019-6
28. American Diabetes Association. (2023). Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Suppl 1), S158–S190.
29. Baig M, Saeed M, Shafiq M, et al. Awareness of dyslipidemia and its consequences in diabetic patients: a multicenter study. J Family Med Prim Care. 2020;9(2):987–991.
30. Toth, P. (2016). Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 171.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
